Texas Permanent School Fund Corp Has $6.21 Million Stock Position in Shockwave Medical, Inc. (NASDAQ:SWAV)

Texas Permanent School Fund Corp lowered its stake in Shockwave Medical, Inc. (NASDAQ:SWAVFree Report) by 3.2% during the third quarter, according to its most recent Form 13F filing with the SEC. The firm owned 31,211 shares of the company’s stock after selling 1,038 shares during the period. Texas Permanent School Fund Corp owned approximately 0.08% of Shockwave Medical worth $6,214,000 as of its most recent filing with the SEC.

A number of other hedge funds also recently modified their holdings of SWAV. Raymond James & Associates boosted its stake in Shockwave Medical by 1.8% in the first quarter. Raymond James & Associates now owns 4,644 shares of the company’s stock valued at $963,000 after buying an additional 81 shares in the last quarter. Bank of New York Mellon Corp boosted its stake in Shockwave Medical by 2.6% in the first quarter. Bank of New York Mellon Corp now owns 151,238 shares of the company’s stock valued at $31,361,000 after buying an additional 3,771 shares in the last quarter. Rhumbline Advisers boosted its stake in Shockwave Medical by 1.5% in the first quarter. Rhumbline Advisers now owns 35,441 shares of the company’s stock valued at $7,349,000 after buying an additional 526 shares in the last quarter. Vontobel Holding Ltd. acquired a new stake in Shockwave Medical in the first quarter valued at about $407,000. Finally, Canada Pension Plan Investment Board boosted its stake in shares of Shockwave Medical by 36.3% during the first quarter. Canada Pension Plan Investment Board now owns 800 shares of the company’s stock valued at $166,000 after purchasing an additional 213 shares in the last quarter. Institutional investors own 87.35% of the company’s stock.

Wall Street Analyst Weigh In

A number of analysts have recently commented on the company. Morgan Stanley cut their price target on Shockwave Medical from $284.00 to $223.00 and set an “overweight” rating on the stock in a research note on Monday, December 4th. SVB Leerink assumed coverage on Shockwave Medical in a research note on Monday, October 16th. They set an “outperform” rating and a $263.00 price target on the stock. Needham & Company LLC cut their price target on Shockwave Medical from $265.00 to $260.00 and set a “buy” rating on the stock in a research note on Tuesday, November 7th. Finally, Leerink Partnrs reissued an “outperform” rating on shares of Shockwave Medical in a research note on Monday, October 16th. Two research analysts have rated the stock with a hold rating and six have assigned a buy rating to the company. According to MarketBeat, Shockwave Medical presently has a consensus rating of “Moderate Buy” and a consensus target price of $263.00.

Check Out Our Latest Research Report on SWAV

Insiders Place Their Bets

In other Shockwave Medical news, CEO Douglas Evan Godshall sold 5,000 shares of Shockwave Medical stock in a transaction that occurred on Wednesday, November 15th. The stock was sold at an average price of $174.08, for a total value of $870,400.00. Following the completion of the sale, the chief executive officer now directly owns 136,057 shares in the company, valued at $23,684,802.56. The sale was disclosed in a filing with the SEC, which is available at the SEC website. In other Shockwave Medical news, CEO Douglas Evan Godshall sold 5,000 shares of Shockwave Medical stock in a transaction that occurred on Wednesday, November 15th. The stock was sold at an average price of $174.08, for a total value of $870,400.00. Following the completion of the sale, the chief executive officer now directly owns 136,057 shares in the company, valued at $23,684,802.56. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, VP Trinh Phung sold 203 shares of the business’s stock in a transaction that occurred on Thursday, December 7th. The shares were sold at an average price of $171.63, for a total value of $34,840.89. Following the sale, the vice president now owns 29,037 shares of the company’s stock, valued at approximately $4,983,620.31. The disclosure for this sale can be found here. Over the last three months, insiders sold 54,096 shares of company stock worth $10,881,425. 3.40% of the stock is owned by corporate insiders.

Shockwave Medical Price Performance

Shockwave Medical stock opened at $233.71 on Monday. The stock’s 50 day moving average is $205.15 and its 200 day moving average is $206.41. The company has a debt-to-equity ratio of 1.22, a current ratio of 14.43 and a quick ratio of 13.19. The firm has a market cap of $8.62 billion, a P/E ratio of 36.40, a P/E/G ratio of 10.03 and a beta of 0.88. Shockwave Medical, Inc. has a one year low of $157.00 and a one year high of $315.95.

Shockwave Medical Profile

(Free Report)

ShockWave Medical, Inc, a medical device company, develops intravascular lithotripsy (IVL) technology for the treatment of calcified plaque in patients with peripheral and coronary vascular, and heart valve diseases in the United States and internationally. The company offers products for the treatment of peripheral artery disease (PAD), including M5 IVL catheter and M5+ IVL catheter, which are five-emitter catheters for use in our IVL system in medium-diameter vessels; S4 IVL catheter, a four-emitter catheter for use in IVL system in small-diameter vessels; and L6 IVL catheter, a six-emitter catheter for use in IVL System in large diameter vessels.

Further Reading

Institutional Ownership by Quarter for Shockwave Medical (NASDAQ:SWAV)

Receive News & Ratings for Shockwave Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Shockwave Medical and related companies with MarketBeat.com's FREE daily email newsletter.